Adenosin Life Medical
Life Medical Sweden AB is a privately held pharmaceutical company who acquired the rights to Adenosin Life Medical in markets outside the USA and Canada.
Kjerstin Gatenbeck, CEO of Life Medical Sweden AB, was previously responsible for adenosine at Item Development AB.
Adenosin Life Medical is marketed and sold in the following markets:
Sweden – Life Medical Sweden AB
Norway – Life Medical Sweden AB
Denmark – Life Medical Sweden AB
Germany – Carinopharm GmbH
Finland and Baltic states – SAM Nordic Oy
Turkey – Abfen Farma
Adenosin Life Medical Sweden AB
VD - Styrelseledamot/CEO - Member of the board
Kjerstin Gatenbeck has thirty years experience from the pharmaceutical industry,
where she spent ten years with Lederle Corporation in sales and clinical research. She was
as Clinical Research Manager responsible for clinical development programs in several
product areas. In 1994 she joined Item Development AB as responsible for
the product Adenosin.
At Item Development she was responsible for Medical management of Adenosin including clinical
development, registration and medical information, as well as Marketing of the product in the
Nordic area at Item Development AB.
Kjerstin Gatenbeck holds a degree as Registered Nurse from SIHUS, the National Swedish
School of Advanced Nursing Education.
Chairman and Founder of Life Equity Group
Dr Gatenbeck previously held leading positions in the European and US Pharmaceutical industry, a career including being Vice President of Pharmacia and Pharmacia Upjohn with global responsibility for several Therapy and Business Areas. Dr Gatenbeck has also been CEO and President of the Karolinska University Hospital in Stockholm, one of Europe’s leading university hospitals.
He has extensive experience of corporate governance as board member of several public and private companies in Europe and Asia. Presently, Dr Gatenbeck serves as Chairman of the Board of Akademikliniken Group Holding AB, Vice Chairman of Industrifonden and on the Boards of Christian Berner Tech Trade AB, Dataflow Group PTY and Tunstall Healthcare Group Ltd. He is also a Board Member of Silviahemmet Foundation, Cancerföreningen and trustee of HM Gustav V anniversary fund.
Dr Gatenbeck has also a number of public assignments for the Swedish Medical and Biotech community and have previously been Chairman of Swecare Foundation.
He serves as a Senior Industry Advisor to EQT.
Dr Gatenbeck holds a MD and a PhD from the Karolinska Institute, Stockholm.
Styrelsemedlem/Member of the board
Mr Anders Wiklund has been an advisor to the Biotechnology industry since 1997, when he formed Wiklund International Inc. The firm focuses on advice in the areas of Long Range Planning, mergers, partnering strategy, product acquisitions, out licensing as well as divestments/assets sales. Mr Wiklund spent almost thirty years with the Pharmacia Group of companies in various executive positions including ten years as CEO and President of KabiVitrum Inc. and KabiPharmacia Inc. in the United States. He has also served as President of Pharmacia Development Corp., Executive Vice President of Pharmacia US Inc and Vice President of Pharmacia Upjohn. As an advisor Mr Wiklund has worked with public and private life science companies in the USA, Canada and Scandinavia, and he was also a cofounder of Esperion Therapeutics Inc.
Presently Mr Wiklund is Chairman of IRRAS AB and Board Member of EffRx SA.
Mr Wiklund holds a Master of Pharmacy degree from Stockholm, Sweden, where he also studied Business Administration.